Plasma Cell Neoplasms and Related Disorders

Slide 1 · Plasma Cell Neoplasms and Related Disorders

Clonal plasma cells • paraprotein biology • organ injury • related entities

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Distinguish a monoclonal immunoglobulin from a specific plasma cell neoplasm.

Connect clonal plasma cell biology to bone, kidney and immune complications.

Recognize myeloma morphology, immunophenotype and core investigations.

Compare MGUS, smoldering disease, plasmacytoma, AL amyloidosis and IgM-associated lymphoma.

Slide 3 · Plasma cells are terminally differentiated B cells

Mature B-cell clone

Plasma-cell differentiation

Immunoglobulin secretion

Antigen-experienced B lymphocytes can differentiate into antibody-secreting plasma cells.

Normal humoral responses are polyclonal, with diverse heavy- and light-chain combinations.

A neoplastic plasma cell population arises from one clone and typically produces one dominant immunoglobulin species.

Clonality links a marrow cell population to its secreted paraprotein.

Slide 4 · The unifying lesion is a monoclonal secretory clone

Tumor-derived immunoglobulin or immunoglobulin fragments often act as circulating tumor markers.

Pathology can result from tissue growth, properties of the secreted protein, or loss of normal antibody production.

A serum monoclonal component is evidence of a clone, not by itself a diagnosis of myeloma.

Clonal plasma cells

M component / free chains

Variable organ consequences

Slide 5 · Why the paraprotein matters

It offers a measurable marker of secretory clone activity.

Its physical properties can increase viscosity or form tissue deposits.

Excess free light chains may be filtered and injure renal tubules.

A monoclonal protein may also be present in a clinically silent precursor state.

Slide 6 · Immunoglobulin architecture explains protein patterns

Stylized intact immunoglobulin: H₂L₂

Violet: Heavy chains | Gold: Light chains

An intact antibody consists of two heavy chains and two light chains.

Neoplastic plasma cells may produce excess unpaired light chains.

Some tumors secrete only light chains; Rare related disorders secrete heavy-chain fragments.

Secretory imbalance is central to serum, urine and tissue abnormalities.

Slide 7 · Why free light chains can appear in urine

Excess free light chains

Glomerular filtration

Urinary excretion / tubular exposure

Intact immunoglobulins are generally too large for normal glomerular filtration.

Free κ or λ chains are smaller and may enter urine as Bence Jones proteins.

Urinary light chains can signal a clone and contribute directly to kidney injury.

Slide 8 · A skewed light-chain ratio indicates clonality

Polyclonal secretion

Numerous antibody-producing clones

Both light-chain classes contribute

Broad immunoglobulin diversity

Clonal secretion

Single dominant secretory population

κ or λ predominance

Restricted immunoglobulin species

Normal plasma cell populations collectively produce κ and λ light chains.

A dominant κ- or λ-restricted clone creates an imbalanced free-light-chain pattern.

Light-chain restriction supports neoplasia when integrated with marrow morphology and clinical findings.

Slide 9 · M component is not interchangeable with malignancy

MGUS may have a measurable paraprotein without organ injury.

Smoldering disease has substantial clonal burden but remains clinically asymptomatic.

Symptomatic myeloma reflects malignant plasma cells accompanied by characteristic tissue or organ injury.

IgM paraproteins may arise from a lymphoplasmacytic B-cell lymphoma rather than myeloma.

Slide 10 · The related disorders form a clinical family

Precursor

MGUS / smoldering

Plasma cell tumor

Myeloma / plasmacytoma

Protein injury

AL amyloidosis

IgM lymphoma

LPL / Waldenström

Plasma cell myeloma, plasmacytoma and precursor plasma cell proliferations share secretory clonality.

AL amyloidosis can reflect a small plasma cell clone with disproportionately severe protein-mediated disease.

Waldenström macroglobulinemia is an IgM-mediated syndrome usually associated with lymphoplasmacytic lymphoma.

Heavy-chain disease reflects rare secretion of heavy-chain fragments.

Slide 11 · Three axes organize the differential diagnosis

Extent of clonal cells

Nature of monoclonal protein

Tissue and organ damage

Clonal burden: Is there a small clone, widespread marrow involvement, or a localized mass?

Secreted protein: Intact immunoglobulin, free light chain, IgM, or heavy-chain fragment?

Clinical harm: Lytic bone destruction, renal toxicity, amyloid deposition, or hyperviscosity?

Slide 12 · Multiple myeloma: Systemic plasma cell neoplasm

The characteristic lesion is multifocal marrow-based plasma cell proliferation.

Osteolytic skeletal destruction is a major pathologic manifestation.

Hypercalcemia, renal injury, anemia and impaired humoral immunity explain much of the clinical burden.

Marrow plasma-cell expansion

Osteolytic skeletal lesions

Organ injury / immune suppression

Slide 13 · Myeloma is predominantly a disease of older adults

Maximal incidence around 65–70 years.

Occurrence is higher in men and in people of African descent.

Age and epidemiology create clinical suspicion; Diagnosis still depends on clonal and organ-level findings.

Epidemiologic patterns are context—not diagnostic criteria.

Slide 14 · IGH rearrangements are recurrent genetic drivers

IGH locus rearrangement

Proto-oncogene deregulation

Clonal advantage

Plasma cell myeloma is genetically heterogeneous.

Rearrangements involving the immunoglobulin heavy-chain locus at 14q32 are frequent.

Partner genes include cell-cycle regulators such as CCND1 and CCND3.

Convergent consequences include altered proliferation and tumor persistence.

Slide 15 · Genomic progression is not a single linear pathway

Growth and survival

Cyclin D pathway deregulation

NF-κB-associated survival changes

Marrow niche support

Aggressiveness / risk

17p/TP53 loss

MYC lesions in aggressive disease

Variable accompanying abnormalities

Deletion of 17p involving TP53 is associated with an adverse outcome.

Alterations affecting NF-κB signaling can enhance B-cell survival.

MYC rearrangements may occur in highly aggressive forms, including plasma cell leukemia.

Diverse genetic lesions complicate simple one-marker disease classification.

Slide 16 · NF-κB alterations favor plasma cell survival

Signaling-pathway alterations

NF-κB activity

Myeloma-cell survival

NF-κB is a transcriptional network supporting B-cell survival.

Myeloma genomes frequently harbor mutations in signaling components of this pathway.

Sustained prosurvival signaling helps maintain the malignant clone.

Slide 17 · IL-6 connects malignant cells to the marrow niche

Myeloma and stromal cells

IL-6 signaling

Clonal growth / survival

IL-6 is an important plasma-cell growth and survival factor.

Both tumor cells and resident marrow stromal cells may produce IL-6.

High IL-6 levels in active disease were associated with worse prognosis in the Robbins discussion.

Slide 18 · Bone marrow stroma contributes beyond cytokines

Direct physical interactions between myeloma cells and stromal cells favor tumor growth and survival.

Tumor cells also alter the normal balance between bone-forming and bone-resorbing cells.

Marrow pathology is therefore an interaction between the neoplastic clone and its microenvironment.

Neoplastic plasma cell

Stromal-cell contact / cytokines

Survival and skeletal injury

Slide 19 · Osteoclast activation initiates destructive bone disease

Myeloma-derived CCL3

Increased osteoclast formation

Bone resorption / hypercalcemia

Myeloma-derived CCL3 (MIP-1α) augments osteoclast formation through several mechanisms.

Osteoclast activity increases mineralized-bone resorption.

Net skeletal loss explains the characteristic osteolytic lesions and contributes to elevated calcium.

Bone destruction is biologically driven—not merely mechanical tumor expansion.

Slide 20 · Osteoblast inhibition prevents effective repair

Myeloma-associated Wnt modulators

Osteoblast inhibition

Failure of balanced remodeling

Tumor-derived regulators of Wnt signaling can strongly suppress osteoblast activity.

Resorption continues while compensatory bone formation is impaired.

This coupling defect helps explain persistent, sharply lytic lesions.

Slide 21 · Bone destruction reflects remodeling uncoupling

Osteoclast side

CCL3-associated formation

Increased bone resorption

Release of calcium

Osteoblast side

Wnt pathway modulation

Reduced new bone formation

Poor structural repair

Heightened osteoclast function removes existing bone.

Depressed osteoblast function prevents adequate replacement.

The imbalance produces osteopenia or focal osteolysis and increases fracture risk.

Slide 22 · Skeletal involvement favors the axial skeleton

The vertebrae, ribs, skull and pelvis among commonly involved sites.

Long-bone and shoulder-girdle sites can also be affected.

The distribution contributes to back pain, fractures and neurologic compression syndromes.

Slide 23 · Osteolytic lesions arise within marrow

Schematic cortical / marrow bone destruction

Plasma cell masses begin in the medullary compartment and erode cancellous bone.

Progressive destruction may extend into the cortex.

Localized defects can coexist with diffuse demineralization.

This is a simplified anatomical schematic, not a radiograph.

Slide 24 · Structural failure explains pain and fractures

Osteolytic remodeling

Weak bone architecture

Pain / pathologic fracture

Loss of cancellous and cortical bone reduces load-bearing capacity.

Vertebral fractures are particularly frequent in myeloma.

A fracture, spinal lesion or severe focal pain can be the clinical clue to marrow disease.

Slide 25 · Myeloma plasma cells retain recognizable features

Schematic — not a histologic specimen

Eccentric nucleus

Golgi hof

Many tumor cells preserve an eccentrically located nucleus.

A pale perinuclear zone represents a prominent Golgi apparatus.

Morphology may resemble normal plasma cells despite biologic malignancy.

Slide 26 · Cytologic atypia varies substantially

Relatively mature morphology

Eccentric nucleus

Perinuclear clearing

Variable atypia

Immature or pleomorphic morphology

Prominent nucleolus

Vesicular chromatin

Occasional bizarre or multinucleated forms

Some clones contain relatively mature plasma cells with coarse chromatin.

Plasmablasts show more open chromatin and prominent nucleoli.

Bizarre or multinucleated forms may also be present.

Appearance alone cannot determine systemic organ injury or replace clonality assessment.

Slide 27 · Intracellular immunoglobulin creates inclusion variants

Cytoplasmic changes

Flame cells

Mott cells

Russell bodies

Nuclear-appearing inclusion

Dutcher bodies

Associated with secretory protein accumulation

Not unique to myeloma

Flame cells exhibit conspicuously reddish cytoplasm.

Mott cells contain multiple grape-like cytoplasmic immunoglobulin accumulations.

Russell bodies are intracytoplasmic globular inclusions.

Dutcher bodies are intranuclear-appearing immunoglobulin inclusions.

Slide 28 · Marrow infiltration may be subtle or extensive

Scattered clonal cells

Expanding marrow infiltrate

Normal hematopoiesis displaced

Clonal plasma cells may occupy scattered interstitial positions.

In advanced infiltration they can replace normal hematopoietic elements.

Marrow suppression contributes to anemia and affects diagnostic sampling.

The degree of infiltration must be assessed alongside the whole clinical syndrome.

Slide 29 · Myeloma can become extramedullary

Advanced disease may infiltrate lymph nodes and soft tissue organs.

Spleen, liver, kidney and lung involvement are described.

Rarely, circulating tumor cells become sufficiently prominent to produce plasma cell leukemia.

The usual presentation remains marrow-centered; Extramedullary spread changes the disease pattern.

Slide 30 · CD138 and light-chain restriction support lineage

Plasma-cell identification

CD138 (syndecan-1)

Cytoplasmic immunoglobulin

Marrow morphologic context

Clonal / aberrant features

κ or λ restriction

Often CD56 expression

Must integrate with clinical context

Myeloma plasma cells express CD138 (syndecan-1).

They often express CD56, which can help recognize an abnormal plasma cell population.

Cytoplasmic κ or λ light-chain restriction supports monoclonality.

Immunophenotype is interpreted with morphology, protein tests and clinical injury.

Slide 31 · Three processes account for myeloma manifestations

Tumor mass

Bone and marrow effects

M protein

Light chains / viscosity

Immune deficit

Reduced normal Ig

Tissue growth: Skeletal damage and replacement of marrow.

Paraprotein toxicity: Renal tubular injury, deposits and altered blood flow.

Suppression of normal humoral immunity: Susceptibility to infections.

Slide 32 · CRAB organizes characteristic end-organ injury

C | Hypercalcemia

Osteoclast-mediated bone resorption

R | Renal impairment

Light chains plus additional insults

A | Anemia

Marrow replacement and other factors

B | Bone lesions

Lytic lesions, pain and fractures

CRAB is a clinicopathologic framework; Abnormalities need attribution to the plasma cell disorder.

Slide 33 · Hypercalcemia is a consequence of bone resorption

Excess osteoclastic resorption

Elevated serum calcium

Neurologic / gastrointestinal / renal effects

Increased osteoclastic activity releases calcium from bone.

Neurologic effects include lethargy, weakness and confusion.

Constipation and polyuria are characteristic systemic manifestations.

Hypercalcemia can intensify renal impairment.

Slide 34 · Free light chains can be toxic to renal tubules

Circulating monoclonal light chains

Urinary filtration / tubular exposure

Tubular injury and renal dysfunction

Excess light chains are filtered at the glomerulus and delivered to tubular structures.

Tubular epithelial toxicity is an important mechanism of myeloma kidney.

Kidney function may decline even when skeletal findings do not dominate.

Slide 35 · Renal dysfunction is multifactorial

Protein-associated injury

Tubular exposure to free chains

AL deposits in susceptible cases

Variable patient-specific effects

Other contributors

Hypercalcemia

Hemodynamic and additional factors

Often more than one process

Bence Jones light-chain excretion is emphasized as a major contributing factor.

Hypercalcemia further compromises renal physiology.

AL amyloid deposition may also involve the kidney.

Clinical evaluation should not attribute every elevation in creatinine to a single mechanism.

Slide 36 · AL amyloidosis represents toxic protein deposition

Monoclonal light-chain production

Misfolding / amyloid deposition

Tissue dysfunction

A monoclonal plasma cell proliferation may secrete amyloidogenic light chains.

A predominance of λ-associated chains in AL disease.

Some patients have overt myeloma; Others harbor only a relatively small marrow clone.

Clinical phenotype follows the distribution of tissue deposits.

Slide 37 · Suppression of polyclonal immunoglobulin impairs defense

Clonal plasma cell expansion

Normal Ig production falls

Recurrent bacterial infections

Myeloma often reduces normal immunoglobulin production.

Loss of humoral protection increases susceptibility to bacterial infections.

Cellular immunity is relatively less affected description.

Recurrent infection can dominate morbidity despite a demonstrable serum paraprotein.

Slide 38 · Rouleaux reflects altered plasma protein composition

Elevated serum proteins

Reduced red-cell repulsion

Rouleaux on peripheral smear

High immunoglobulin concentrations favor red cell stacking in linear arrays.

Rouleaux may be noted on blood smears in multiple myeloma.

It is not specific: Other causes of elevated immunoglobulin can produce the same finding.

Slide 39 · Hyperviscosity is possible but not universal in myeloma

Abundant paraprotein can increase serum viscosity.

IgA or IgG3 aggregates in selected patients.

Clinical hyperviscosity is more characteristic of high-IgM lymphoplasmacytic disease.

Protein subtype and physical behavior matter in addition to paraprotein quantity.

Slide 40 · Monoclonal-protein evaluation uses complementary tests

Detect restricted protein

Type immunoglobulin / light chain

Correlate with marrow and organs

Serum and urine protein electrophoresis screen for abnormal restricted proteins.

Immunofixation identifies the heavy-chain class and κ/λ identity.

Free-light-chain testing identifies light-chain predominance, including cases without intact M protein.

Interpretation requires bone marrow and organ-damage assessment.

Slide 41 · Electrophoretic patterns: Narrow versus broad

Broad polyclonal pattern

Monoclonal band / spike

Qualitative schematic only — not patient data, quantified electrophoresis or a diagnostic result

A polyclonal immunoglobulin distribution forms a broader background pattern.

A predominant monoclonal immunoglobulin often creates a sharp restricted band or spike.

Protein electrophoresis detects a possible M component; It does not identify the complete disease entity.

Slide 42 · Immunofixation determines the paraprotein isotype

Restricted serum/urine band

Heavy-chain assignment

κ or λ light-chain typing

Antisera recognizing IgG, IgA or IgM identify the heavy-chain class.

Separate κ and λ antisera reveal the restricted light-chain component.

An example such as IgG-κ describes the monoclonal molecule, not disease stage or organ risk.

Suppression of unrelated immunoglobulins may be detected concurrently.

Slide 43 · Secretory patterns create diagnostic blind spots

Detectable secretion

Intact immunoglobulin

Free light chains

Both may coexist

Little or no conventional M protein

Occasional nonsecretory myeloma

Protein studies may be unrevealing

Marrow and organ assessment remain important

Common myeloma clones secrete intact immunoglobulin, often with excess free light chains.

Other clones produce light chains alone.

Rare tumors are nonsecretory: A missing conventional M spike does not completely rule out myeloma.

Marrow findings and tissue consequences remain essential.

Slide 44 · IgG and IgA predominate among myeloma M proteins

The Robbins description identifies IgG as the leading secreted isotype.

IgA is the next most common intact immunoglobulin class.

IgM-, IgD- and IgE-associated myelomas are described as uncommon.

Protein isotype alone does not distinguish myeloma from every related clonal disorder.

Slide 45 · Marrow testing establishes the cellular component

Bone marrow morphology

Plasma-cell immunophenotype

Integrated clinicopathologic assessment

Bone marrow examination documents plasma cell infiltration and cytology.

CD138 staining and κ/λ studies help identify and characterize the clone.

Genetic assessment can reveal recurrent structural abnormalities.

The final diagnosis integrates cell findings with laboratory and organ-level evidence.

Slide 46 · Do not interpret a CRAB feature in isolation

Anemia may coexist with a monoclonal gammopathy for unrelated reasons.

Kidney impairment is not automatically caused by a paraprotein.

Bone symptoms require demonstration of characteristic skeletal pathology.

Clinical attribution depends on the combined patient findings.

Identify abnormality

Evaluate alternate causes

Link to clonal disorder if supported

Slide 47 · Myeloma evaluation is a multi-domain process

Clonal cells

Secreted protein

Patient organ status

Identify clonal marrow plasma cells and characterize the immunoglobulin product.

Assess blood counts, serum calcium and renal function.

Investigate characteristic skeletal disease.

Integrate findings instead of relying on one positive test.

No single laboratory test is an adequate stand-alone diagnosis.

Slide 48 · A plasma cell clone has several important mimics

Finding

Supports

Must distinguish from

Clonal marrow cells

Plasma cell proliferation

Clinically silent precursor

Bone lytic lesions

Symptomatic myeloma pattern

Other destructive bone disorders

IgM paraprotein

Monoclonal B-cell process

Lymphoplasmacytic lymphoma

Localized plasma cell mass

Plasmacytoma

Systemic myeloma

Reactive plasmacytosis can accompany chronic immune stimulation. • MGUS and smoldering states may exhibit clonality without myeloma-type symptoms. • IgM lymphoplasmacytic lymphoma is a B-cell neoplasm with plasmacytic differentiation. • An isolated mass needs distinction from generalized marrow disease.

Slide 49 · Chromosomal abnormalities influence prognosis

Genetic feature

Robbins interpretation

Cyclin D1-associated translocation

Relatively favorable association

17p loss involving TP53

Adverse outcome

13q deletion

Adverse association

t(4;14)

More aggressive course

Translocations involving cyclin D1 are described as associated with a relatively favorable outcome. • Deletion 17p, deletion 13q and t(4;14) are associated with more aggressive behavior in the source. • Genetic associations modify risk but require interpretation with the clinical disease state.

Slide 50 · Proteasome inhibition exploits protein-synthesis stress

Heavy immunoglobulin synthesis

Misfolded protein accumulation

Proteasome block → apoptosis

Plasma cells synthesize large amounts of immunoglobulin.

Heavy-/light-chain imbalance increases the burden of misfolded protein.

Proteasome inhibition prevents degradation of unwanted proteins.

Accumulation of damaged proteins can trigger tumor-cell apoptosis.

Slide 51 · Immunomodulatory drugs also alter protein turnover

Lenalidomide action on ubiquitin ligase

Altered target-protein degradation

Reduced myeloma growth

Thalidomide-related compounds such as lenalidomide as active therapies.

Lenalidomide can redirect selected ubiquitin ligase activity.

Growth-essential proteins become targeted for degradation.

The biological explanation differs from direct inhibition of proteasome catalytic function.

Slide 52 · Bone-directed treatment targets skeletal complications

Suppress resorption

Preserve skeletal integrity

Reduce fracture / calcium burden

Bisphosphonates suppress bone resorption.

Reducing osteoclast-mediated loss decreases fracture and hypercalcemia complications.

This supportive mechanism is distinct from eradication of the malignant clone.

Slide 53 · BCMA-directed CAR-T represents targeted immunotherapy

Mechanism and potential

BCMA-directed T-cell targeting

Deep responses in selected patients

Immunologic attack on malignant clone

Major toxicities

Cytokine release syndrome

Neurotoxicity

Hypogammaglobulinemia-associated infection

B-cell maturation antigen (BCMA) provides a target on plasma cells.

CAR-T approaches can induce deep remissions in many patients.

The Robbins discussion emphasizes cytokine release syndrome, neurologic toxicity and infection risk.

Benefit and complications both follow potent immune activation and plasma-cell targeting.

Slide 54 · MGUS: Monoclonality without symptomatic neoplasm

Monoclonal gammopathy of undetermined significance is common in older adults.

By definition in the Robbins discussion, patients are asymptomatic with a relatively small serum M component.

There is no clinical evidence of a symptomatic plasma cell neoplasm at the time of classification.

Its relevance is the possibility of later progression.

Small plasma-cell clone

Monoclonal component

No attributable symptomatic disease

Slide 55 · MGUS is a biologic precursor, not simply a lab artifact

Early clonal plasma cells

Shared genetic lesions

Potential later progression

Clonal cells can contain chromosome rearrangements also seen in myeloma.

This overlap supports a multistep model of plasma cell tumor development.

Most clinically detected MGUS does not immediately become symptomatic myeloma.

A clonal marker must be interpreted over time.

Slide 56 · MGUS requires longitudinal interpretation

Progression to a symptomatic plasma cell neoplasm in approximately 1% of MGUS patients per year.

The course of an individual clone remains unpredictable.

Periodic surveillance of the M component and urinary free light chains is discussed.

The presence of a clone should not be equated with immediate tissue damage.

Slide 57 · Smoldering myeloma is an asymptomatic intermediate

MGUS

Clinically silent, smaller clone

Smoldering myeloma

Higher clonal burden, no symptoms

Myeloma

Clonal disease with injury

It occupies a clinical middle ground between MGUS and symptomatic myeloma.

There is a greater clonal disease burden than in typical MGUS.

Patients lack the characteristic symptomatic end-organ manifestations at presentation.

Meaningful long-term risk of progression.

Slide 58 · Progression is possible—not inevitable on a timetable

Clinically silent clone

Evolution in tumor biology

Potential symptomatic disease

MGUS and smoldering myeloma represent different baseline burdens and risks.

Biologic progression involves acquired changes and altered tumor-host interactions.

Clinical transformation is recognized by the disease phenotype, not merely elapsed time.

The source reports uncertainty in predicting individual evolution.

Slide 59 · Solitary plasmacytoma is a localized plasma cell tumor

Solitary bone lesion

Plasma-cell mass in bone

May share sites with myeloma

Progression to systemic disease is common

Extraosseous lesion

Often upper aerodigestive tract

Local presentation

Local treatment can be curative

A single bone or soft-tissue mass may contain neoplastic plasma cells.

Some patients have a small detectable circulating M component.

Extent-of-disease evaluation distinguishes a solitary lesion from disseminated myeloma.

Natural history differs markedly by osseous versus extraosseous site.

Slide 60 · Osseous and extraosseous plasmacytomas diverge

Solitary mass discovered

Determine osseous vs soft tissue

Assess systemic risk and spread

Bone plasmacytomas frequently evolve into multiple myeloma over long follow-up.

Upper respiratory tract extraosseous lesions often behave more locally.

Anatomic localization and careful staging are therefore clinically consequential.

Slide 61 · A small plasma cell clone can cause systemic AL disease

Clonal burden

Sometimes limited plasma cell population

M component may be present

No requirement for diffuse bone lesions

Tissue damage

Misfolded light chains

Amyloid fibril deposition

Organ-specific dysfunction

AL amyloidogenic protein may arise even when marrow infiltration is minor.

Organ damage results from abnormal light-chain deposition, rather than solely tumor bulk.

The extent of symptoms can be disproportionate to measured marrow tumor burden.

This distinguishes protein-mediated disorders from a purely mass-effect model.

Slide 62 · Heavy-chain disease is a rare paraprotein disorder

The defining secretory feature is a free immunoglobulin heavy-chain fragment.

It may accompany different B-cell lymphoproliferative diseases.

Lymphoplasmacytic lymphoma and small-bowel marginal zone disease among associations.

It is a secretory category, not a synonym for plasma cell myeloma.

Slide 63 · Lymphoplasmacytic lymphoma differs from myeloma

Myeloma

Plasma cell neoplasm

Marrow and lytic skeletal pathology

Often IgG / IgA or free chains

Lymphoplasmacytic lymphoma

Mature B cells plus plasma cells

Frequently IgM secretion

Hyperviscosity and systemic lymphoid spread

It is a mature B-cell neoplasm with substantial plasmacytic differentiation.

The typical monoclonal product is IgM.

Generalized lymphoid-organ infiltration and IgM-mediated symptoms are characteristic.

Unlike typical myeloma, destructive skeletal lesions are not a characteristic feature.

Slide 64 · MYD88 mutation is central to LPL biology

MYD88 alteration

NF-κB-associated signaling

Tumor-cell survival

Acquired MYD88 mutations in virtually all cases.

MYD88 is an adaptor involved in signals activating NF-κB.

Prosurvival signaling provides a mechanistic basis for B-cell persistence.

The molecular association supports understanding but must be interpreted with phenotype.

Slide 65 · LPL marrow combines lymphoid and plasma cell forms

Marrow composition

Small B lymphocytes

Plasmacytoid cells / plasma cells

Often accompanying mast cells

Useful phenotype

B-cell population expresses CD20

Surface immunoglobulin on B cells

Matching secreted Ig from plasma cells

Marrow infiltrates contain small lymphocytes, plasmacytoid lymphocytes and mature plasma cells.

Mast cell hyperplasia is often present.

Russell and Dutcher inclusions can accompany immunoglobulin production.

CD20-positive lymphoid cells and the immunoglobulin-producing plasma cell component are clonally related.

Slide 66 · Waldenström macroglobulinemia is an IgM syndrome

IgM-secreting B-cell clone

Elevated intravascular IgM

Hyperviscosity and antibody-mediated effects

High intravascular IgM can markedly increase plasma viscosity.

The syndrome most commonly develops in lymphoplasmacytic lymphoma.

Circulatory symptoms reflect the high concentration and large molecular size of IgM.

IgM excess also produces cold-related antibody effects in selected patients.

Slide 67 · IgM hyperviscosity has characteristic organ effects

Eyes

Venous congestion

Brain

Headache / dizziness

Hemostasis

Mucosal bleeding

Retinal venous congestion can cause visual impairment.

Sluggish circulation contributes to headache, dizziness and altered alertness.

Interactions with platelets or clotting factors can produce bleeding.

Severe symptoms may require urgent reduction of circulating IgM.

Slide 68 · Cold IgM may cause immune-mediated complications

Cold agglutinin activity

IgM binds red cells in the cold

May lead to hemolysis

Antibody-mediated effect

Cryoglobulinemia

Cold-dependent protein precipitation

Raynaud phenomenon

Cold urticaria

Cold agglutinins are IgM antibodies capable of binding red cells at low temperatures.

Autoimmune hemolysis may occur in a subset of LPL patients.

Cryoglobulins precipitate at reduced temperatures and can cause Raynaud phenomena or urticaria.

These effects differ mechanistically from simple hyperviscosity.

Slide 69 · IgM reduction and lymphoma control are distinct goals

Immediate protein effect

Plasmapheresis removes circulating IgM

Relieves hyperviscosity manifestations

Underlying neoplasm

CD20-directed and other lymphoma therapies

BTK pathway inhibition

Requires ongoing clinical management

Plasmapheresis can rapidly reduce predominantly intravascular IgM and its rheologic effects.

Lymphoma-directed therapies reduce the clone producing the protein.

Responsiveness to anti-CD20 therapy and BTK inhibition.

This distinction separates urgent syndrome management from long-term clone control.

Slide 70 · Key contrast: Myeloma versus Waldenström syndrome

Characteristic

Multiple myeloma

LPL / Waldenström

Dominant clone

Plasma cells

B lymphocytes with plasma cells

Typical M protein

IgG, IgA or free chains

IgM

Bone destruction

Characteristic lytic lesions

Not characteristic

Major protein harm

Tubular light chains / AL / viscosity

Viscosity / cold IgM effects

Tumor compartment

Marrow, skeletal sites

Marrow, nodes, spleen, liver

Slide 71 · Clinicopathologic vignette: Bone pain and proteinuria

An older adult has persistent back pain, a destructive skeletal lesion, anemia and urinary monoclonal free light chains.

DISCUSSION

Which mechanism explains focal bone loss?

Why might the kidney be affected through a second mechanism?

What three categories of investigations are needed before concluding myeloma?

Slide 72 · Clinicopathologic vignette: Asymptomatic M component

An asymptomatic adult has a newly discovered monoclonal serum band but no identified myeloma-type organ injury.

DISCUSSION

Why does an M component alone not establish symptomatic myeloma?

Which tissue and organ findings would change classification?

Why is longitudinal reassessment justified?

Slide 73 · Clinicopathologic vignette: Visual and bleeding symptoms

An older adult presents with blurred vision, headaches and mucosal bleeding; Investigations identify a marked monoclonal IgM component.

DISCUSSION

Which paraprotein is most closely linked to this syndrome?

What cellular neoplasm should be considered?

Why can reducing circulating protein help before tumor burden changes?

Slide 74 · Common diagnostic reasoning errors

Calling every M spike “multiple myeloma.”

Assuming all renal dysfunction in monoclonal gammopathy is cast-related.

Treating IgM paraproteinemia and IgG/IgA myeloma as identical mechanisms.

Inferring histologic malignancy from cytologic atypia alone.

Using a single older textbook threshold as a complete contemporary diagnostic algorithm.

Slide 75 · Integrative framework: Clone → protein → tissue injury

Clone identity

Paraprotein biology

Organ phenotype

Diagnostic classification

Identify the cellular clone and its differentiation stage.

Determine the type, quantity and physicochemical effects of monoclonal protein.

Assess marrow, skeleton, kidney, circulation and immune competence.

Classify the disorder by its combined morphologic and clinical phenotype.

Slide 76 · Core distinctions to retain

MGUS and smoldering disease are clinically silent at recognition, but differ in clonal burden.

Myeloma often causes lytic bone disease, renal toxicity and loss of normal immunoglobulin.

Localized plasmacytoma requires staging to exclude systemic involvement.

AL damage may be severe despite modest clonal burden.

Waldenström syndrome reflects large IgM-mediated rheologic and immune effects.

Slide 77 · Source, terminology and interpretation

Primary reference: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026), Chapter 13, pp. 552–556.

Topic coverage incorporates the adjacent textbook sections for MGUS, smoldering myeloma, plasmacytoma and lymphoplasmacytic lymphoma.

Diagnostic and prognostic frameworks are presented as described in this textbook; they are not substitutes for a current IMWG or WHO/ICC clinical classification consultation.

Original diagrams are native PowerPoint schematics, not patient specimens or reproduced textbook figures.